0.1490
+0.0192
+(14.79%)
At close: April 8 at 11:53:23 AM GMT+2
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Tord Labuda M.Sc., Ph.D. | Chief Executive Officer | -- | -- | -- |
| Mr. Erik Kullgren | Chief Financial Officer | -- | -- | -- |
| Dr. Anders Sandberg Ph.D. | Chief Scientific Officer | -- | -- | 1972 |
| Mr. Sebastian Hansson | Business Development Director | -- | -- | -- |
Alzinova AB (publ)
Pepparedsleden 1
Mölndal, 431 83
Sweden
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer's disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in Mölndal, Sweden.
Corporate Governance
Alzinova AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available